Johnson & Johnson (JNJ) Upgraded at Vetr

Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a report released on Wednesday morning. They currently have $147.14 price target on the stock.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a hold rating in a report on Wednesday, October 18th. Citigroup raised their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a buy rating in a report on Monday, October 23rd. Jefferies Group upgraded shares of Johnson & Johnson from a hold rating to a buy rating and raised their target price for the stock from $145.00 to $157.00 in a report on Wednesday, October 11th. Argus raised their target price on shares of Johnson & Johnson from $145.00 to $165.00 and gave the stock a positive rating in a report on Wednesday, October 18th. Finally, BMO Capital Markets raised their target price on shares of Johnson & Johnson to $161.00 and gave the stock an outperform rating in a report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson currently has a consensus rating of Hold and a consensus target price of $145.47.

Shares of Johnson & Johnson (JNJ) traded down $0.94 on Wednesday, hitting $140.12. 4,665,582 shares of the stock traded hands, compared to its average volume of 6,090,915. The firm has a market cap of $378,960.50, a PE ratio of 24.33, a P/E/G ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.68 EPS. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

Hedge funds have recently bought and sold shares of the stock. OLD Point Trust & Financial Services N A lifted its stake in Johnson & Johnson by 2.2% in the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock valued at $8,113,000 after acquiring an additional 1,321 shares during the last quarter. Lynch & Associates IN raised its position in shares of Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after purchasing an additional 841 shares during the period. Welch & Forbes LLC raised its position in shares of Johnson & Johnson by 0.9% in the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after purchasing an additional 6,730 shares during the period. Oakbrook Investments LLC raised its position in shares of Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after purchasing an additional 9,375 shares during the period. Finally, Janney Montgomery Scott LLC raised its position in shares of Johnson & Johnson by 0.5% in the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock valued at $102,110,000 after purchasing an additional 3,533 shares during the period. Institutional investors and hedge funds own 65.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Upgraded at Vetr” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/23/johnson-johnson-jnj-upgraded-at-vetr.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit